Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
- Author:
Kyung Ho LEE
1
;
Tae Sun HAN
;
Changsu HAN
;
Won-Myong BAHK
;
Soo-Jung LEE
;
Ashwin A. PATKAR
;
Prakash S. MASAND
;
Chi-Un PAE
Author Information
- Publication Type:Brief Report
- From:Clinical Psychopharmacology and Neuroscience 2023;21(3):594-598
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice.
Methods:Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected.
Results:The changes of CGI-CB (Z = −3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = −3.483, p ＜ 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint.No significant adverse events were observed.
Conclusion:This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
